Biogen’s recently FDA-approved drug Aduhelm costs an upward of $56,000 per year, and this may have a domino effect of impacts: “If Aduhlem is…
A recent study suggests that sargramostim, a drug used for patients undergoing chemotherapy as well as bone marrow and blood stem cell transplants, may…
For the retired neurologist Daniel Gibbs, a diagnosis of early-stage Alzheimer’s not only gave him a sense of relief, but also a clear path…
Following the FDA’s approval of the new Alzheimer’s drug Aduhelm (aducanumab), retired neurologist Daniel Gibbs spoke with Being Patient in a recent LiveTalk about…
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
Imran Sherwani, olympic gold medalist, was diagnosed with early-onset Alzheimer’s in 2019, and revealed his diagnosis this month. Sherwani revels in the life he’s…
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…